APVO

NASD Aptevo Therapeutics, Inc.
Oct 6, 2026 · 5:42 PM ET LAST TRADE Market Closed

$1.83 ↑ +0.04 (+1.95%) Trading Up from the previous close of $1.80, $0.09 below the day’s high of $1.92

YTD change
-80.59%
vs 20-day SMA
+0.37%
vs 200-day SMA
-65.93%

Price ranges

Previous day
$1.75 $1.85
open $1.76 close $1.80
+$0.04 (+2.27%)
Today
$1.79 $1.92
open $1.82 now $1.83
+$0.01 (+0.55%)
Past week
$1.75 $1.91
from $1.91 now $1.83
-$0.08 (-4.19%)
Past month
$1.71 $1.99
from $1.74 now $1.83
+$0.09 (+5.17%)
This year
$1.37 $10.70
from $9.43 now $1.83
-$7.60 (-80.59%)

Price & Performance

-2.44 (-57.55%) / 6M

$1.40$2.91$4.41$5.92Apr 6Jul 7Oct 5

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good
  • The stock is 100.0% away from all-time highs of $287,179.00
  • APVO is down 81% since the beginning of the year
  • APVO is down 93% over the past 12 months
  • APVO is up 5% over the past 1 month
  • 8% of all APVO investors are betting against APVO

APVO reads not so good: price sits above one of the two key moving averages, the 12-month move is +27.7%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-5.31
Earnings momentum -42.9% Quarterly EPS growth
Quarterly change -42.9%

Valuation

P/E ratio 0.03
Enterprise value $-3434540.0
Beta 2.55

Balance sheet & scale

IncomeN/A
RevenueN/A
Cash$9.8M
Debt$4.2K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $4.8M

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527, and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $402.98 -0.01%
MRNA Moderna, Inc. $203.21 +6.95%
RVMD Revolution Medicines, Inc. $207.68 +0.50%
ROIV Roivant Sciences Ltd. $35.78 +0.17%
BNTX BioNTech SE Sponsored ADR $97.64 +0.76%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.